Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.70 |
| ▸ | TP53 | P04637 | 2/20 | 0.70 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.70 |
| ▸ | MITF | O75030 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | DOT1L | Q8TEK3 | 4/20 | 0.67 |
| ▸ | DNMT3B | Q9UBC3 | 3/20 | 0.59 |
| ▸ | DNMT1 | P26358 | 2/20 | 0.59 |
| ▸ | PNMT | P11086 | 1/20 | 0.59 |
| ▸ | PRMT7 | Q9NVM4 | 1/20 | 0.57 |
| ▸ | NADK | O95544 | 1/20 | 0.56 |
| ▸ | AHCY | P23526 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20097018 | 0.88 | ADORA3 (0.70) | ADORA3TP53PAX8SMN1; SMN2SLC29A1 | |
| SCHEMBL20096994 | 0.84 | DOT1L (0.80) | DOT1LDNMT3BDNMT1PNMTPRMT7 | |
| SCHEMBL6907808 | 0.83 | DOT1L (0.69) | DOT1LDNMT3BDNMT1PNMTPRMT7 | |
| Kinetin Riboside SCHEMBL19583061 | 0.83 | ADORA3 (1.00) | ADORA3TP53PAX8SMN1; SMN2SLC29A1 | |
| Kinetin Riboside SCHEMBL14713468 | 0.83 | ADORA3 (1.00) | ADORA3TP53PAX8SMN1; SMN2SLC29A1 | |
| Kinetin Riboside SCHEMBL3190252 | 0.83 | ADORA3 (1.00) | ADORA3TP53PAX8SMN1; SMN2SLC29A1 | |
| Kinetin Riboside SCHEMBL14713232 | 0.83 | ADORA3 (1.00) | ADORA3TP53PAX8SMN1; SMN2SLC29A1 | |
| Kinetin Riboside SCHEMBL3190271 | 0.83 | ADORA3 (1.00) | ADORA3TP53PAX8SMN1; SMN2SLC29A1 | |
| Kinetin Riboside SCHEMBL217034 | 0.83 | ADORA3 (1.00) | ADORA3TP53PAX8SMN1; SMN2SLC29A1 | |
| Kinetin Riboside SCHEMBL3339041 | 0.83 | ADORA3 (1.00) | ADORA3TP53PAX8SMN1; SMN2SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190262371-A1 | METHODS AND COMPOSITION FOR THE TREATMENT OF RNA VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190262371-A1 | METHODS AND COMPOSITION FOR THE TREATMENT OF RNA VIRAL INFECTIONS | POLRMT, EIF2AK2, NSUN3 | ADORA3 2754/4885TP53 583/4885PAX8 2873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.